北美结直肠癌诊断市场预测至 2028 年 - COVID-19 影响和区域分析 - 按方式 [成像测试(结肠镜检查、CT 结肠镜检查、柔性乙状结肠镜检查、胶囊内窥镜检查等)和粪便测试(粪便免疫化学测试 (FIT)) 、基于愈创木脂的粪便潜血测试和粪便 DNA 测试)]和最终用户(医院、诊断实验室、癌症研究机构等)

Historic Data: 2021-2022   |   Base Year: 2023   |   Forecast Period: 2024-2028


No. of Pages: 148    |    Report Code: BMIRE00028834    |    Category: Life Sciences

North America Colorectal Cancer Diagnostics Market

2023年北美结直肠癌诊断市场价值为43.1586亿美元,预计到2028年将达到66.2126亿美元。预计2023年至2028年的复合年增长率为8.9% 2028年。

新产品的推出推动北美结直肠癌诊断市场

结直肠癌诊断市场的主要参与者生产各种设备,帮助减轻结直肠癌和其他相关适应症(如结肠息肉、克罗恩病、结肠炎和肠易激综合症)的负担。 2022 年 7 月,顶级胃肠道 (GI) 实践网络美国消化健康 (USDH) 宣布通过安装全国最大的 Genious 智能胃肠道内窥镜模块,实现人工智能辅助结肠镜检查的商业化。这些模块有望帮助医生实时识别难以检测和潜在癌变的息肉。随着该设备的推出,宾夕法尼亚州东南部、西南部和中部的患者现在可以使用功能增强的人工智能辅助结肠镜检查。 2020年9月,奥林巴斯公司宣布推出ENDO-AID,这是一个由人工智能(AI)驱动的尖端平台。该平台包括 ENDO-AID CADe 应用程序 (app),这是一种计算机辅助内窥镜方法,用于检测结肠的不同状况。这个新的人工智能平台能够实时显示自动检测到的可疑病变,并与 EVIS X1 结合使用。因此,频繁的开发和新产品的推出推动了北美结直肠癌诊断市场的增长。

北美结直肠癌诊断市场概述

北美结直肠癌诊断市场分为美国、加拿大和墨西哥。根据美国临床肿瘤学会的数据,结直肠癌是美国男性和女性中第三大最常见的癌症。到 2023 年,美国估计将有 153,020 名成年人被诊断患有结直肠癌。这些数字包括 106,970 例结肠癌新病例(54,420 名男性和 52,550 名女性)和 46,050 例直肠癌新病例(27,440 名男性和 18,610 名女性)。此外,2020 年约有 1,880,725 人被诊断出患有结直肠癌。虽然老年人更容易患结直肠癌,但年轻人的癌症发病率正在增加。男性终生患结直肠癌的风险约为二十二分之一,女性约为二十四分之一。美国临床肿瘤学会 (ASCO) 估计,到 2023 年,美国将有约 52,550 人死于结直肠癌。到 2022 年,美国每年进行超过 600,000 例治疗结肠疾病的手术。根据美国癌症协会的数据,局限性结肠癌的五年生存率为 91%,局限性直肠癌的五年生存率为 90%。总体而言,过去 20 年来,随着筛查和治疗的改进,结直肠癌死亡率有所下降。此外,筛查通过降低结直肠癌发病率和提高生存率来降低结直肠癌死亡率。 2018 年美国癌症协会 CRC 筛查指南建议,45 岁及以上的成年人必须根据患者偏好和检测可用性,通过高灵敏度粪便测试或目视检查进行定期筛查。 2021 年 5 月,美国预防服务工作组更改了结直肠癌筛查建议。成年人被诊断出结直肠癌的平均风险并建议开始筛查的年龄从50岁降低到45岁。此外,该国政府支持结直肠癌的研究。研究人员致力于开发一种可用于预防、检测和治疗结直肠癌的先进技术。结直肠癌联盟是世界上最大的非营利性结直肠癌患者倡导组织,致力于资助结直肠癌研究。 2020 年,额外提供 110 万美元资金,通过研究补助金支持个别科学家。因此,由于上述因素,北美结直肠癌诊断市场可能会在预测期内得到推动。

 北美结直肠癌诊断市场收入和到 2028 年的预测(百万美元)

北美结直肠癌诊断市场细分

北美结直肠癌诊断市场分为模式、最终用户和国家。

根据模式,北美结直肠癌诊断市场分为影像学测试和粪便测试。 2023年,影像测试领域在北美结直肠癌诊断市场中占据更大份额。影像测试市场进一步细分为结肠镜检查、CT结肠造影、柔性乙状结肠镜检查、胶囊内窥镜检查等。基于粪便的测试市场细分为粪便免疫化学测试 (fit)、基于愈创木脂的粪便潜血测试 (gFOBT) 和粪便 DNA 测试。

基于对于最终用户,北美结直肠癌诊断市场分为医院、诊断实验室、癌症研究机构等。 2023年,医院细分市场占据北美结直肠癌诊断市场的最大份额。

根据国家/地区,北美结直肠癌诊断市场分为美国、加拿大、墨西哥。 2023年,美国占据北美结直肠癌诊断市场的最大份额。

美敦力公司(Medtronic Plc);照明公司;临床基因组学技术有限公司; EDP生物科技公司;表观基因组学公司; F.霍夫曼-拉罗氏有限公司;奎斯特诊断公司;西门子医疗集团;布鲁克公司;和 Eiken Chemical Co., Ltd 是北美结直肠癌诊断市场的领先公司之一。



North America Colorectal Cancer Diagnostics Strategic Insights

Strategic insights for North America Colorectal Cancer Diagnostics involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.

strategic-framework/north-america-colorectal-cancer-diagnostics-market-strategic-framework.webp
Get more information on this report

North America Colorectal Cancer Diagnostics Report Scope

Report Attribute Details
Market size in 2023 US$ 4,315.86 Million
Market Size by 2028 US$ 6,621.26 Million
Global CAGR (2023 - 2028) 8.9%
Historical Data 2021-2022
Forecast period 2024-2028
Segments Covered By 方式
  • 影像学检查
  • 粪便检查
By 最终用户
  • 医院
  • 诊断实验室
  • 癌症研究机构
Regions and Countries Covered 北美
  • 美国
  • 加拿大
  • 墨西哥
Market leaders and key company profiles
  • Bruker Corp
  • Clinical Genomics Technologies Pty Ltd
  • EDP Biotech Corp
  • Eiken Chemical Co., Ltd.
  • Epigenomics AG
  • F. Hoffmann-La Roche Ltd
  • Illumina Inc
  • Medtronic Plc
  • Quest Diagnostics Inc
  • Siemens Healthineers AG
  • Get more information on this report

    North America Colorectal Cancer Diagnostics Regional Insights

    The regional scope of North America Colorectal Cancer Diagnostics refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.

    geography/north-america-colorectal-cancer-diagnostics-market-geography.webp
    Get more information on this report

    The List of Companies - North America Colorectal Cancer Diagnostics Market

    1. Bruker Corp                                             
    2. Clinical Genomics Technologies Pty Ltd  
    3. EDP Biotech Corp                                         
    4. Eiken Chemical Co., Ltd.                       
    5. Epigenomics AG                                       
    6. F. Hoffmann-La Roche Ltd                   
    7. Illumina Inc        
    8. Medtronic Plc    
    9. Quest Diagnostics Inc                           
    10. Siemens Healthineers AG                     
    Frequently Asked Questions
    How big is the North America Colorectal Cancer Diagnostics Market?

    The North America Colorectal Cancer Diagnostics Market is valued at US$ 4,315.86 Million in 2023, it is projected to reach US$ 6,621.26 Million by 2028.

    What is the CAGR for North America Colorectal Cancer Diagnostics Market by (2023 - 2028)?

    As per our report North America Colorectal Cancer Diagnostics Market, the market size is valued at US$ 4,315.86 Million in 2023, projecting it to reach US$ 6,621.26 Million by 2028. This translates to a CAGR of approximately 8.9% during the forecast period.

    What segments are covered in this report?

    The North America Colorectal Cancer Diagnostics Market report typically cover these key segments-

  • 方式 (影像学检查, 粪便检查)
  • 最终用户 (医院, 诊断实验室, 癌症研究机构)
  • What is the historic period, base year, and forecast period taken for North America Colorectal Cancer Diagnostics Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Colorectal Cancer Diagnostics Market report:

  • Historic Period : 2021-2022
  • Base Year : 2023
  • Forecast Period : 2024-2028
  • Who are the major players in North America Colorectal Cancer Diagnostics Market?

    The North America Colorectal Cancer Diagnostics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • Bruker Corp
  • Clinical Genomics Technologies Pty Ltd
  • EDP Biotech Corp
  • Eiken Chemical Co., Ltd.
  • Epigenomics AG
  • F. Hoffmann-La Roche Ltd
  • Illumina Inc
  • Medtronic Plc
  • Quest Diagnostics Inc
  • Siemens Healthineers AG
  • Who should buy this report?

    The North America Colorectal Cancer Diagnostics Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the North America Colorectal Cancer Diagnostics Market value chain can benefit from the information contained in a comprehensive market report.